XENON PHARMACEUTICALS INC. (XENE) Q3 2025 TL;DR Summary
Xenon Pharmaceuticals reported significantly widening operational losses driven by accelerated Research & Development (R&D) investment across its neuroscience pipeline. The company remains in a pre-product sales development phase, operating as a single reportable segment assessed primarily by net loss.
Financial Performance (9M Ended Sept 30, 2025): Net Loss for the nine-month period increased substantially to \((240.6 million) from \)(168.6 million) in the prior year, resulting in diluted EPS of $(3.05). R&D spending drove the bu
...